Biliary tract cancers: Epidemiology, molecular pathogenesis and genetic risk associations

Chinese Clinical Oncology

Volumn 5, Issue 5, 2016, Pages

  Marcano Bonilla, Lorena ^a,b   Mohamed, Essa A ^a   Mounajjed, Taofic ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Biliary tract neoplasms; Cholangiocarcinoma (CCA); Gallbladder neoplasms; Genetic predisposition to disease; Molecular pathology

Indexed keywords

BILIARY TRACT CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; GENETIC ASSOCIATION; GENETIC ASSOCIATION STUDY; GENETIC RISK; HUMAN; MOLECULAR PATHOLOGY; REVIEW; BILIARY TRACT NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY;

BILIARY TRACT NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PATHOLOGY, MOLECULAR;

EID: 84999040153     PISSN: 23043865     EISSN: 23043873     Source Type: Journal    
DOI: 10.21037/cco.2016.10.09     Document Type: Review

References (222)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71.
2. Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol 2009;20:146-59.
3. Yang JD, Kim B, Sanderson et al. Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. Am J Gastroenterol 2012;107:1256-62.
4. SEER Training Modules. Introduction to Pancreatic & Biliary Tract Cancers. Cited 2016 May 12. Available online: http://training.seer.cancer.gov/biliary/intro/
5. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28:3531-40.
6. Rajaraman P, Melin B, Wang Z, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet 2012;131:1877-88.
7. Zhang K, Civan J, Mukherjee S, et al. Genetic variations in colorectal cancer risk and clinical outcome. World J Gastroenterol 2014;20:4167-77.
8. Chang YT, Chang MC, Huang KW, et al. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. J Gastroenterol Hepatol 2014;29:1119-25.
9. American Cancer Society. What is bile duct cancer? Available online: http://www.cancer.org/cancer/bileductcancer/detailedguide/bile-duct-cancer-what-is-bile-duct-cancer
10. de Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med 1999;341:1368-78.
11. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-73.
12. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755-62.
13. Lowe RC, Afdhal NH, Anderson CD. Epidemiology, pathogenesis, and classification of cholangiocarcinoma. Available online: http://www.uptodate.com/contents/epidemiology-pathogenesis-and-classification-of-cholangiocarcinoma
14. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015;29:221-32.
15. Arroyo GF, Gentile A, Parada LA. Gallbladder cancer: South American experience. Chin Clin Oncol 2016;5:67.
16. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-64.
17. Diehl AK. Epidemiology of gallbladder cancer: a synthesis of recent data. J Natl Cancer Inst 1980;65:1209-14.
18. Mehrotra B. Gallbladder Cancer: Epidemiology, Risk Factors, Clinical Features, and Diagnosis. Accessed on July 29, 2015. Available online: http://www.uptodate.com/contents/gallbladder-cancer-epidemiology-risk-factors-clinical-features-and-diagnosis
19. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006;118:1591-602.
20. Henley SJ, Weir HK, Jim MA, et al. Gallbladder Cancer Incidence and Mortality, United States 1999-2011. Cancer Epidemiol Biomarkers Prev 2015;24:1319-26.
21. Castro FA, Koshiol J, Hsing AW, et al. Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. Int J Cancer 2013;133:1664-71.
22. Mosadeghi S, Liu B, Bhuket T, et al. Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000-2011 Surveillance, Epidemiology and End Results registry. Hepatol Res 2016;46:669-77.
23. Alberts SR, Kelly JJ, Ashokkumar R, et al. Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973-2007. Int J Circumpolar Health 2012;71:17521.
24. Sithithaworn P, Yongvanit P, Duenngai K, et al. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:301-8.
25. Sriamporn S, Pisani P, Pipitgool V, et al. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health 2004;9:588-94.
26. Vatanasapt V, Martin N, Sriplung H, et al. Cancer incidence in Thailand, 1988-1991. Cancer Epidemiol Biomarkers Prev 1995;4:475-83.
27. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol 2008;24:349-56.
28. Hsing AW, Bai Y, Andreotti G, et al. Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Int J Cancer 2007;121:832-8.
29. Paraskevopoulos JA, Dennison AR, Ross B, et al. Primary carcinoma of the gallbladder: a 10-year experience. Ann R Coll Surg Engl 1992;74:222-4.
30. Kaushik SP. Current perspectives in gallbladder carcinoma. J Gastroenterol Hepatol 2001;16:848-54.
31. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995;75:171-90.
32. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004;4:695-706.
33. Kanthan R, Senger JL, Ahmed S, et al. Gallbladder Cancer in the 21st Century. J Oncol 2015;2015:967472.
34. Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167-76.
35. Su CH, Lui WY, P'eng FK. Relative prevalence of gallstone diseases in Taiwan. A nationwide cooperative study. Dig Dis Sci 1992;37:764-8.
36. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54:173-84.
37. Lee TY, Lee SS, Jung SW, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008;103:1716-20.
38. Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145:521-36.
39. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33.
40. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.
41. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-6.
42. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-11.
43. Bergquist A, Glaumann H, Persson B, et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998:311-6.
44. Chapman MH, Webster GJ, Bannoo S, et al. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012;24:1051-8.
45. Lazaridis KN, LaRusso NF. The Cholangiopathies. Mayo Clin Proc 2015;90:791-800.
46. Eaton JE, Juran BD, Atkinson EJ, et al. A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:980-90.
47. Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007;102:1677-82.
48. Fevery J, Henckaerts L, Van Oirbeek R, et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver Int 2012;32:214-22.
49. Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Br Med Bull 2015;114:53-64.
50. Bergquist A, Broomé U. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:643-56.
51. Rizvi S, Eaton JE, Gores GJ. Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol 2015;13:2152-65.
52. Karlsen TH, Melum E, Franke A. The utility of genome wide association studies in hepatology. Hepatology 2010;51:1833-42.
53. Karlsen TH, Schrumpf E, Boberg KM. Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2010;24:655-66.
54. Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 2016;48:510-8.
55. Grainge MJ, West J, Solaymani-Dodaran M, et al. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer 2009;100:178-80.
56. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007;5:1221-8.
57. Shebl FM, Andreotti G, Rashid A, et al. Diabetes in relation to biliary tract cancer and stones: a population-based study in Shanghai, China. Br J Cancer 2010;103:115-9.
58. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005;128:620-6.
59. Lee BS, Park EC, Park SW, et al. Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea. World J Gastroenterol 2015;21:502-10.
60. Engeland A, Tretli S, Austad G, et al. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes Control 2005;16:987-96.
61. Hsing AW, Sakoda LC, Rashid A, et al. Body size and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2008;99:811-5.
62. Ren HB, Yu T, Liu C, et al. Diabetes mellitus and increased risk of biliary tract cancer: systematic review and meta-analysis. Cancer Causes Control 2011;22:837-47.
63. Jing W, Jin G, Zhou X, et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012;21:24-31.
64. Zhang LF, Zhao HX. Diabetes mellitus and increased risk of extrahepatic cholangiocarcinoma: a meta-analysis. Hepatogastroenterology 2013;60:684-7.
65. Lee MS, Hsu CC, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20.
66. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
67. Chaiteerakij R, Yang JD, Harmsen WS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013;57:648-55.
68. Ling S, Feng T, Ke Q, et al. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep 2014;31:2611-8.
69. Jang MH, Lee YJ, Kim H. Intrahepatic cholangiocarcinoma arising in Caroli's disease. Clin Mol Hepatol 2014;20:402-5.
70. Dayton MT, Longmire WP Jr, Tompkins RK. Caroli's Disease: a premalignant condition? Am J Surg 1983;145:41-8.
71. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999;10 Suppl 4:308-11.
72. Lipsett PA, Pitt HA, Colombani PM, et al. Choledochal cyst disease. A changing pattern of presentation. Ann Surg 1994;220:644-52.
73. Scott J, Shousha S, Thomas HC, et al. Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature. Am J Gastroenterol 1980;73:113-9.
74. Arora A, Mukund A, Thapar S, et al. Anomalous pancreaticobiliary junction. J Pediatr Gastroenterol Nutr 2014;58:e13.
75. Kamisawa T, Kuruma S, Chiba K, et al. Biliary carcinogenesis in pancreaticobiliary maljunction. J Gastroenterol 2016. [Epub ahead of print].
76. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002;89:962-70.
77. Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci 2010;101:579-85.
78. Bragazzi MC, Cardinale V, Carpino G, et al. Cholangiocarcinoma: Epidemiology and risk factors. Transl Gastrointest Cancer 2012;1:21-32.
79. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-25.
80. Lim JH. Liver flukes: the malady neglected. Korean J Radiol 2011;12:269-79.
81. Kurathong S, Lerdverasirikul P, Wongpaitoon V, et al. Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology 1985;89:151-6.
82. Jang KT, Hong SM, Lee KT, et al. Intraductal papillary neoplasm of the bile duct associated with Clonorchis sinensis infection. Virchows Arch 2008;453:589-98.
83. Sripa B, Bethony JM, Sithithaworn P, et al. Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop 2011;120 Suppl 1:S158-68.
84. Honjo S, Srivatanakul P, Sriplung H, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer 2005;117:854-60.
85. Zhang GW, Lin JH, Qian JP, et al. Identification of risk and prognostic factors for patients with clonorchiasis-associated intrahepatic cholangiocarcinoma. Ann Surg Oncol 2014;21:3628-37.
86. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-14.
87. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
88. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
89. El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009;49:116-23.
90. Li M, Li J, Li P, et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol 2012;27:1561-8.
91. Zhou HB, Hu JY, Hu HP. Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World J Gastroenterol 2014;20:5721-9.
92. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012;57:69-76.
93. Zhou Y, Zhao Y, Li B, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer 2012;12:289.
94. Lee CH, Chang CJ, Lin YJ, et al. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 2009;100:1765-70.
95. Vladoianu IR, Chang HR, Pechère JC. Expression of host resistance to Salmonella typhi and Salmonella typhimurium: bacterial survival within macrophages of murine and human origin. Microb Pathog 1990;8:83-90.
96. Kumar S, Kumar S, Kumar S. Infection as a risk factor for gallbladder cancer. J Surg Oncol 2006;93:633-9.
97. Mager DL. Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med 2006;4:14.
98. Hornick RB, Greisman SE, Woodward TE, et al. Typhoid fever: pathogenesis and immunologic control. N Engl J Med 1970;283:686-91.
99. Parry CM, Hien TT, Dougan G, et al. Typhoid fever. N Engl J Med 2002;347:1770-82.
100. Vogelsang TM, Bøe J. Temporary and chronic carriers of Salmonella typhi and Salmonella paratyphi B. J Hyg (Lond) 1948;46:252-61.
101. Khatri NS, Maskey P, Poudel S, et al. Gallbladder carriage of Salmonella paratyphi A may be an important factor in the increasing incidence of this infection in South Asia. Ann Intern Med 2009;150:567-8.
102. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005;366:749-62.
103. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004;82:346-53.
104. Merselis JG Jr, Kaye D, Connolly CS, et al. Quantitative bacteriology of the typhoid carrier state. Am J Trop Med Hyg 1964;13:425-9.
105. Levine MM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J Infect Dis 1982;146:724-6.
106. Sinnott CR, Teall AJ. Persistent gallbladder carriage of Salmonella typhi. Lancet 1987;1:976.
107. Shpargel JS, Berardi RS, Lenz D. Salmonella typhi carrier state 52 years after illness with typhoid fever: a case study. Am J Infect Control 1985;13:122-3.
108. Nath G, Singh H, Shukla VK. Chronic typhoid carriage and carcinoma of the gallbladder. Eur J Cancer Prev 1997;6:557-9.
109. Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther 2014;39:745-50.
110. Dutta U, Garg PK, Kumar R, et al. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 2000;95:784-7.
111. Caygill CP, Hill MJ, Braddick M, et al. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 1994;343:83-4.
112. Fukuda K, Kuroki T, Tajima Y, et al. Comparative analysis of Helicobacter DNAs and biliary pathology in patients with and without hepatobiliary cancer. Carcinogenesis 2002;23:1927-31.
113. Chen W, Li D, Cannan RJ, et al. Common presence of Helicobacter DNA in the gallbladder of patients with gallstone diseases and controls. Dig Liver Dis 2003;35:237-43.
114. Huang Y, Fan XG, Wang ZM, et al. Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J Clin Pathol 2004;57:1273-7.
115. Chang JS, Tsai CR, Chen LT. Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study. PLoS One 2013;8:e69981.
116. Bulajic M, Maisonneuve P, Schneider-Brachert W, et al. Helicobacter pylori and the risk of benign and malignant biliary tract disease. Cancer 2002;95:1946-53.
117. Pandey M, Shukla M. Helicobacter species are associated with possible increase in risk of hepatobiliary tract cancers. Surg Oncol 2009;18:51-6.
118. Murphy G, Michel A, Taylor PR, et al. Association of seropositivity to Helicobacter species and biliary tract cancer in the ATBC study. Hepatology 2014;60:1963-71.
119. Leelawat K, Suksumek N, Leelawat S, et al. Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J Trop Med Public Health 2007;38:881-5.
120. Vorobjova T, Nilsson I, Terjajev S, et al. Serum antibodies to enterohepatic Helicobacter spp. in patients with chronic liver diseases and in a population with high prevalence of H. pylori infection. Dig Liver Dis 2006;38:171-6.
121. Murata H, Tsuji S, Tsujii M, et al. Helicobacter bilis infection in biliary tract cancer. Aliment Pharmacol Ther 2004;20 Suppl 1:90-4.
122. Matsukura N, Yokomuro S, Yamada S, et al. Association between Helicobacter bilis in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. Jpn J Cancer Res 2002;93:842-7.
123. Romero S, Archer JR, Hamacher ME, et al. Case report of an unclassified microaerophilic bacterium associated with gastroenteritis. J Clin Microbiol 1988;26:142-3.
124. Zhou D, Wang JD, Weng MZ, et al. Infections of Helicobacter spp. in the biliary system are associated with biliary tract cancer: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25:447-54.
125. Silva CP, Pereira-Lima JC, Oliveira AG, et al. Association of the presence of Helicobacter in gallbladder tissue with cholelithiasis and cholecystitis. J Clin Microbiol 2003;41:5615-8.
126. Pellicano R, Mazzaferro V, Grigioni WF, et al. Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma. World J Gastroenterol 2004;10:598-601.
127. Fox JG, Dewhirst FE, Tully JG, et al. Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol 1994;32:1238-45.
128. Maurer KJ, Ihrig MM, Rogers AB, et al. Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology 2005;128:1023-33.
129. Takayama S, Takahashi H, Matsuo Y, et al. Effect of Helicobacter bilis infection on human bile duct cancer cells. Dig Dis Sci 2010;55:1905-10.
130. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
131. Segura-López FK, Güitrón-Cantú A, Torres J. Association between Helicobacter spp. infections and hepatobiliary malignancies: a review. World J Gastroenterol 2015;21:1414-23.
132. Anatoxins. Available online: http://www.cancer.gov/about-cancer/causes-prevention/risk/substances/aflatoxins
133. World Health Organization. Public Health Strategies for Preventing Anatoxin Exposure. Available online: http://www.who.int/ipcs/events/2005/workshop_report.pdf
134. Tsuchiya Y, Terao M, Okano K, et al. Mutagenicity and mutagens of the red chili pepper as gallbladder cancer risk factor in Chilean women. Asian Pac J Cancer Prev 2011;12:471-6.
135. World Health Organization. International agency for research on cancer. iarc monographs on the evaluation of carcinogenic risks to humans. 2002. Available online: http://monographs.iarc.fr/ENG/Monographs/vol82/mono82.pdf
136. Nogueira L, Foerster C, Groopman J, et al. Association of aflatoxin with gallbladder cancer in Chile. JAMA 2015;313:2075-7.
137. Ikoma T, Tsuchiya Y, Asai T, et al. Ochratoxin A Contamination of Red Chili Peppers from Chile, Bolivia and Peru, Countries with a High Incidence of Gallbladder Cancer. Asian Pac J Cancer Prev 2015;16:5987-91.
138. Ringot D, Chango A, Schneider YJ, et al. Toxicokinetics and toxicodynamics of ochratoxin A, an update. Chem Biol Interact 2006;159:18-46.
139. Yamada K, Kumagai S, Nagoya T, et al. Chemical exposure levels in printing workers with cholangiocarcinoma. J Occup Health 2014;56:332-8.
140. Yamada K, Kumagai S, Kubo S, et al. Chemical exposure levels in printing and coating workers with cholangiocarcinoma (third report). J Occup Health 2015;57:565-71.
141. Yamada K, Kumagai S, Endo G. Chemical exposure levels in printing workers with cholangiocarcinoma (second report). J Occup Health 2015;57:245-52.
142. Kubo S, Nakanuma Y, Takemura S, et al. Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci 2014;21:479-88.
143. Kubo S, Kinoshita M, Takemura S, et al. Characteristics of printing company workers newly diagnosed with occupational cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:809-17.
144. Kumagai S. Two offset printing workers with cholangiocarcinoma. J Occup Health 2014;56:164-8.
145. American Cancer Society. Gallbladder Cancer. 2014. Available online: http://www.cancer.org/acs/groups/cid/ documents/webcontent/003101-pdf.pdf
146. Titapun A, Pugkhem A, Luvira V, et al. Outcome of curative resection for perihilar cholangiocarcinoma in Northeast Thailand. World J Gastrointest Oncol 2015;7:503-12.
147. Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg 2014;149:565-74.
148. Courtin-Tanguy L, Rayar M, Bergeat D, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol 2016;113:575-80.
149. Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol 2016;22:2601-10.
150. Wang Z, Sheng YY, Dong QZ, et al. Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis. World J Gastroenterol 2016;22:3038-51.
151. Miquel JF, Covarrubias C, Villaroel L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology 1998;115:937-46.
152. Yamagiwa H. Mucosal dysplasia of gallbladder: isolated and adjacent lesions to carcinoma. Jpn J Cancer Res 1989;80:238-43.
153. Yamagiwa H, Tomiyama H. Intestinal metaplasia-dysplasia-carcinoma sequence of the gallbladder. Acta Pathol Jpn 1986;36:989-97.
154. Yanagisawa N, Mikami T, Saegusa M, et al. More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages. Cancer Res 2001;61:19-22.
155. Rashid A, Gao YT, Bhakta S, et al. Beta-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res 2001;61:3406-9.
156. Chang HJ, Jee CD, Kim WH. Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am J Surg Pathol 2002;26:758-66.
157. Fava G, Lorenzini I. Molecular pathogenesis of cholangiocarcinoma. Int J Hepatol 2012;2012:630543.
158. Patel T. New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol 2014;49:165-72.
159. Choi J, Ghoz HM, Peeraphatdit T, et al. Aspirin use and the risk of cholangiocarcinoma. Hepatology 2016;64:785-96.
160. Bickenbach K, Galka E, Roggin KK. Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma? Surg Oncol Clin N Am 2009;18:215-24, vii.
161. Taniai M, Higuchi H, Burgart LJ, et al. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090-8.
162. Itatsu K, Zen Y, Ohira S, et al. Immunohistochemical analysis of the progression of flat and papillary preneoplastic lesions in intrahepatic cholangiocarcinogenesis in hepatolithiasis. Liver Int 2007;27:1174-84.
163. Andersen JB. Molecular pathogenesis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2015;22:101-13.
164. Chan-On W, Nairismägi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013;45:1474-8.
165. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45:1470-3.
166. Huang WY, Gao YT, Rashid A, et al. Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: a population-based case-control study in China. Carcinogenesis 2008;29:100-5.
167. Gao Q, Zhao YJ, Wang XY, et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology 2014;146:1397-407.
168. Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun 2015;6:6087.
169. Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun 2014;5:5696.
170. Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015;47:1003-10.
171. Wang LJ, He CC, Sui X, et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 2015;6:5932-46.
172. Chen MH, Chiang KC, Cheng CT, et al. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget 2014;5:2372-89.
173. Churi CR, Shroff R, Wang Y et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014;9:e115383.
174. Moeini A, Sia D, Bardeesy N, et al. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. Clin Cancer Res 2016;22:291-300.
175. Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:1021-1031. e15.
176. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829-40.
177. Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013;44:1216-22.
178. Lee H, Wang K, Johnson A, et al. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol 2016;69:403-8.
179. Craig J. Complex Diseases: Research and Applications Nature Education. 2008. Cited May 17, 2016. Available online: http://www.nature.com/scitable/topicpage/complex-diseases-research-and-applications-748
180. Attia J. Genetic association studies: Principles and applications. Available online: http://www.uptodate.com/contents/genetic-association-studies-principles-and-applications?source=search_result&search=genetic+association+studies&selectedTitle=1%7E68
181. Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association: A: Background concepts. JAMA 2009;301:74-81.
182. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 2002;3:391-7.
183. Cha PC, Zembutsu H, Takahashi A, et al. A genome-wide association study identifies SNP in DCC is associated with gallbladder cancer in the Japanese population. J Hum Genet 2012;57:235-7.
184. Johnson EF, Connick JP, Reed JR, et al. Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges. Drug Metab Dispos 2014;42:9-22.
185. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004;5:211-24.
186. Shimada T. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 2006;21:257-76.
187. Pandey SN, Choudhuri G, Mittal B. Association of CYP1A1 Msp1 polymorphism with tobacco-related risk of gallbladder cancer in a north Indian population. Eur J Cancer Prev 2008;17:77-81.
188. Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000;9:3-28.
189. Tsuchiya Y, Kiyohara C, Sato T, et al. Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese. Clin Biochem 2007;40:881-6.
190. Park SK, Andreotti G, Sakoda LC, et al. Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China. Carcinogenesis 2009;30:606-14.
191. Sangrajrang S, Sato Y, Sakamoto H, et al. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 2009;125:837-43.
192. Dwivedi S, Agrawal S, Singh S, et al. Association of Cytochrome-17 (MspA1) Gene Polymorphism with Risk of Gall Bladder Stones and Cancer in North India. Asian Pac J Cancer Prev 2015;16:5557-63.
193. Hou L, Xu J, Gao YT, et al. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China. Int J Cancer 2006;118:2847-53.
194. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003;348:1170-5.
195. Fine MJ, Ibrahim SA, Thomas SB. The role of race and genetics in health disparities research. Am J Public Health 2005;95:2125-8.
196. Dixit M, Choudhuri G, Mittal B. Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study. Hepatol Res 2006;36:61-9.
197. Hofman MK, Weggemans RM, Zock PL, et al. CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans. J Nutr 2004;134:2200-4.
198. Srivastava A, Pandey SN, Choudhuri G, et al. Role of genetic variant A-204C of cholesterol 7alpha-hydroxylase (CYP7A1) in susceptibility to gallbladder cancer. Mol Genet Metab 2008;94:83-9.
199. Andreotti G, Chen J, Gao YT, et al. Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2008;17:525-34.
200. Báez S, Tsuchiya Y, Calvo A, et al. Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women. World J Gastroenterol 2010;16:372-8.
201. Kaur MP, Guggenheim EJ, Pulisciano C, et al. Cellular accumulation of Cys326-OGG1 protein complexes under conditions of oxidative stress. Biochem Biophys Res Commun 2014;447:12-8.
202. Srivastava A, Srivastava K, Pandey SN, et al. Single-nucleotide polymorphisms of DNA repair genes OGG1 and XRCC1: association with gallbladder cancer in North Indian population. Ann Surg Oncol 2009;16:1695-703.
203. Srivastava K, Srivastava A, Mittal B. Polymorphisms in ERCC2, MSH2, and OGG1 DNA repair genes and gallbladder cancer risk in a population of Northern India. Cancer 2010;116:3160-9.
204. Ding X, Wang K, Wu Z, et al. The Ser326Cys polymorphism of hOGG1 is associated with intrahepatic cholangiocarcinoma susceptibility in a Chinese population Int J Clin Exp Med 2015;8:16294-300.
205. Jiao X, Huang J, Wu S, et al. hOGG1 Ser326Cys polymorphism and susceptibility to gallbladder cancer in Chinese population. Int J Cancer 2007;121:501-5.
206. You SH, Wang X, Huang S, et al. MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma; Mol Med Rep 2013;7:347-51.
207. Vishnoi M, Pandey SN, Modi DR et al. Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor betal-509C>T gene polymorphisms with gallbladder cancer. Hum Immunol 2008;69:360-7.
208. Hsing AW, Sakoda LC, Rashid A, et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Re 2008;68:6442-52.
209. Mishra K, Behari A, Kapoor VK, et al. Vascular endothelial growth factor single-nucleotide polymorphism in gallbladder cancer. J Gastroenterol Hepatol 2013;28:1678-85.
210. Rai R, Sharma KL, Tiwari S, et al. DCC (deleted in colorectal carcinoma) gene variants confer increased susceptibility to gallbladder cancer (Ref. No.: Gene-D-12-01446). Gene 2013;518:303-9.
211. Chaiteerakij R, Juran BD, Aboelsoud MM, et al. Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma. Cancer Med 2015;4:1599-602.
212. Sakoda LC, Gao YT, Chen BE, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 2006;27:1251-6.
213. Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012;38:904-10.
214. Prayong P, Mairiang E, Pairojkul C, et al. An interleukin-6 receptor polymorphism is associated with opisthorchiasis-linked cholangiocarcinoma risk in Thailand. Asian Pac J Cancer Prev 2014;15:5443-7.
215. Castro FA, Koshiol J, Hsing AW, et al. Inflammatory gene variants and the risk of biliary tract cancers and stones: a population-based study in China. BMC Cancer 2012;12:468.
216. Vishnoi M, Pandey SN, Choudhuri G, et al. IL-1 gene polymorphisms and genetic susceptibility of gallbladder cancer in a north Indian population. Cancer Genet Cytogenet 2008;186:63-8.
217. Spear P, Wu MR, Sentman ML, et al. NKG2D ligands as therapeutic targets. Cancer Immun 2013;13:8.
218. Melum E, Karlsen TH, Schrumpf E, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008;47:90-6.
219. Krawczyk M, Höblinger A, Mihalache F, et al. Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. Dig Liver Dis 2013;45:612-5.
220. Kawaguchi M, Kataoka H. MST1 (macrophage stimulating 1 (hepatocyte growth factor-like). Available online: http://atlasgeneticsoncology.org/Genes/MST1ID44411ch3p21.html
221. Shaik AP, Shaik AS, Al-Sheikh YA, et al. Colorectal cancer: A review of the genome-wide association studies in the kingdom of Saudi Arabia. Saudi J Gastroenterol 2015;21:123-8.
222. Gorrell MD. Liver fibrosis: the hepatocyte revisited. Hepatology 2007;46:1659-61.